Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older

This survey study assesses the occurrence of short-term adverse events in adults 60 years or older who received a booster dose of the BNT162B2 mRNA vaccine.

Detalles Bibliográficos
Autores principales: Auster, Oren, Finkel, Uriah, Dagan, Noa, Barda, Noam, Laufer, Alon, Balicer, Ran D., Ben-Shachar, Shay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016488/
https://www.ncbi.nlm.nih.gov/pubmed/35435973
http://dx.doi.org/10.1001/jamanetworkopen.2022.7657
Descripción
Sumario:This survey study assesses the occurrence of short-term adverse events in adults 60 years or older who received a booster dose of the BNT162B2 mRNA vaccine.

Ejemplares similares